← Back to Home

Daewoong Pharmaceutical Reports Phase 1 Data for Autoimmune Drug: Engagement of Two Targets, Efficacy Still to Be Verified

In a single-dose study in healthy adults, plodicitinib achieved peak target occupancy above 90% for both BTK and ITK. This provides preliminary evidence that the drug can bind to its intended targets in humans, but key trials are still needed to determine whether it can improve patients’ conditions.

By SURL BioNews

For a drug to modulate different immune cells simultaneously, researchers must first confirm that it can bind to its intended targets in humans. Plodicitinib (DWP212525), an oral drug being developed by Daewoong Pharmaceutical for autoimmune diseases, has now provided preliminary human evidence of this: in a single-dose study in healthy adults, peak occupancy exceeded 90% for both main targets. However, the study has not yet answered whether it can improve patients’ conditions.

Daewoong Pharmaceutical announced on November 17 that it had presented these data on November 9 at ACR Convergence 2026, the American College of Rheumatology’s annual meeting, held in Orlando, United States. Both the company’s press release and the Seoul Economic Daily reported that the single ascending dose portion of the first-in-human trial included 44 healthy adults; the meeting abstract recorded that 43 participants completed the study and described its randomized, double-blind, placebo-controlled design.

Plodicitinib is being developed to act simultaneously on JAK3, ITK and BTK, three proteins involved in immune signaling. ITK and BTK are involved in the activation of T cells and B cells, respectively. The company hopes to modulate multiple immune response pathways through this approach and assess its potential use in rheumatoid arthritis, systemic lupus erythematosus and Sjögren’s syndrome. These remain development objectives, rather than therapeutic uses established by this trial.

The most concrete findings from this study concerned BTK and ITK. Researchers analyzed target occupancy in peripheral blood immune cells and found that peak occupancy exceeded 90% for both at higher doses. This figure reflects the extent of drug binding to the targets; it cannot be interpreted as a 90% improvement in disease, nor does it establish that all three intended targets achieve the same degree of engagement in humans.

Pharmacokinetic analysis showed that drug exposure in the body increased with dose; the meeting abstract further noted that the increase was more than dose-proportional. This means that subsequent dose adjustments will need to be assessed alongside changes in exposure in the body to gradually identify a suitable range for repeated dosing.

Regarding safety, no serious adverse events occurred during the study, and all treatment-emergent adverse events were mild. However, these results came from a small number of healthy participants receiving a single dose and primarily provide early tolerability information. The safety and actual efficacy of continued dosing in patients with autoimmune diseases who require long-term treatment still need to be verified separately.

Daewoong Pharmaceutical said that a multiple ascending dose study is underway, with the aim of completing Phase 1 in the first quarter of 2027. The next key question is whether repeated dosing can maintain appropriate target engagement and acceptable safety, before taking these human pharmacological findings into patient trials to test whether they can translate into benefits in disease control.

References

  1. Plataforma Media
  2. Daewoong Pharmaceutical via PR Newswire
  3. Seoul Economic Daily